Thalia Therapeutics (LON:THAT – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported GBX (0.09) EPS for the quarter, Digital Look Earnings reports.
Thalia Therapeutics Price Performance
LON:THAT opened at GBX 0.61 on Wednesday. Thalia Therapeutics has a twelve month low of GBX 0.40 and a twelve month high of GBX 0.95. The stock has a market cap of £10.89 million and a PE ratio of -3.61.
Thalia Therapeutics Company Profile
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Further Reading
- Five stocks we like better than Thalia Therapeutics
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
Receive News & Ratings for Thalia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thalia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
